Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epithelial membrane antigen (Mucin-1) (EMA (also known as MUC1))
- Target
- EMA (also known as MUC1)
- Molecular classification
- Transmembrane glycoprotein, Mucin family protein, Cell surface antigen, Other (specifically not a GPCR, ion channel, enzyme, or transporter)
01
Overview
Epithelial membrane antigen (EMA), also recognized as Mucin-1 (MUC1) and CD227, is a heavily glycosylated transmembrane mucin glycoprotein found on the apical surface of glandular and ductal epithelial cells as well as some hematopoietic cells. It is used widely in immunohistochemistry to characterize epithelial origin tumors, especially adenocarcinomas, and serves as a diagnostic and prognostic marker in cancer. EMA/MUC1 plays roles in cell adhesion, signaling, tumor progression, and immune response. The molecule is associated with poor prognosis in many cancers and is targeted for experimental antibody-based therapies. Its heterogeneous and broad distribution across different tissue types introduces challenges in therapeutic targeting and diagnostic specificity[1][5][7][9][11].
- Other names
- EMAMucin-1/MUC1EpisialinCD227
02
Mechanism of action
Antibody-dependent cellular cytotoxicity (for anti-MUC1/EMA antibodies)\nInhibition of mucin-related signaling\nBlockage of cell adhesion and cell proliferation pathways
03
Biological functions
Cell adhesionCell signalingImmune response (role as antigen in immunohistochemistry)Cell proliferationTumor progression
04
Disease associations
Cancer (various adenocarcinomas, breast, skin, endometrium, kidney, thyroid, stomach, pancreas, lung, colon, ovary, prostate, cervix)Diagnosis of epithelial tumorsPrognostic biomarker in cancerSome lymphomas (Hodgkin’s lymphoma, anaplastic large cell lymphoma)Meningiomas, sarcomas
05
Safety considerations
Off-target effects due to expression in normal epitheliaVariable reactivity in some non-epithelial tumors and plasma cells, possibly leading to diagnostic ambiguityResistance to therapy due to heterogeneity of expression
06
Interacting drugs
Drugs targeting MUC1/EMA include therapeutic antibodies (such as AS1402 and other investigational agents); no widely approved direct MUC1/EMA drugs
1 more in the full profile.
07
Biomarkers
EMA/MUC1 immunohistochemistry for identifying epithelial origin cancersUsed to subtype tumors and as a prognostic marker
Beyond the preview
Go deeper on Epithelial membrane antigen (Mucin-1) (EMA (also known as MUC1)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epithelial membrane antigen (Mucin-1) (EMA (also known as MUC1)).